Eli Lilly | LLY - Operating Expenses

Stock Price
1,081.18
Daily Change
77.72 7.75%
Monthly
3.81%
Yearly
30.88%
Q1 Forecast
1,005.21

Eli Lilly reported $9.21B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Abbott USD 9.21B 17M Dec/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Baxter International USD 2.63B 95.8M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Medtronic USD 7.26B 283M Sep/2025
Merck USD 10.16B 558M Dec/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Novo Nordisk DKK 42.77B 3.48B Jun/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Prestige Brands USD 194.44M 16.67M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sanofi EUR 10.71B 1.32B Dec/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Zoetis USD 5.4B 3.94B Sep/2025